Randox News / Uncategorized

Randox Labs to Debut Quantiplasma Antibody Array for Biomarker Discovery

Randox Labs to Debut Quantiplasma Antibody Array for Biomarker Discovery in Q3

Randox Laboratories will launch in the next quarter a new antibody array product for biomarker discovery. The offering, called the Quantiplasma Array, is designed to complement the firm’s menu of more focused screening tools.

Stuart McGregor B.Sc. (Hons) in Chemistry, Ph.D. in Organic Chemistry, Research & Development Scientist, New Technologies & Biochip Array Technology

Stuart McGregor, a research scientist at the Crumlin, UK-based firm, said the new array is a “very important” product for Randox. “It allows customers to go right into biomarker discovery,” he told BioArray News this week. “Most of our arrays are clinical arrays or research arrays, containing, in general, very well characterized biomarkers,” McGregor said.

Located in Northern Ireland, Randox has in recent years worked to expand its menu of biochips. Last year, the firm debuted two arrays for metabolic syndrome studies (BAN 8/17/2010) and in 2009 it launched several multi-marker drugs-of-abuse testing arrays (BAN 12/1/2009).

The company currently offers 11 focused multiplex protein arrays and six multiplex molecular arrays and also makes customer-designed chips.

Randox hopes that markers discovered with its new Quantiplasma Array will translate to more custom projects, McGregor said. “Ultimately, we are providing customers with a tool for biomarker discovery and hopefully in the future, if new biomarkers can be discovered through the use of this array, there is an opportunity for customers to have clinical arrays developed very quickly,” he said.

Randox introduced the Quantiplasma Array earlier this month. The monoclonal antibody microarray is designed to monitor the level of multiple proteins simultaneously in human plasma. Each kit contains 300 unique monoclonal antibodies and can be used to assess the plasma proteome dynamics of normal and disease state plasma samples for identification of novel biomarkers (BAN 5/17/2011).

According to McGregor, the antibodies on the array have been generated against “normal plasma, a number of different cancers, including breast cancer, colon cancer, and lung cancer, and other diseases including inflammatory diseases and metabolic disorders.” Because of this, he said the array offers users access to “quite a range of different disease states and normal proteins.”

Ideally, Randox customers will “start with the question of what biomarkers are possible to identify in a disease area and we would suggest that they run the normal samples against their disease pool of samples,” McGregor said. “That way they will identify proteins that are differentially expressed between the normal state and the disease state, and that will be the start of their investigation using this array.”

Reference: http://www.genomeweb.com/

Comments are closed.